FPT-EUROPE
18.8.2021 08:32:11 CEST | Business Wire | Press release
FPT Europe, a subsidiary of the global technology services provider FPT Corporation, has announced the collaboration with innogy Czech, a leading energy company providing natural gas, electricity and heating solutions, as well as clean mobility solutions, to migrate the innogy Czech’s entire SAP R/3-based ERP infrastructure to the SaaS cloud. As the general contractor of the project, FPT will support the customer to migrate the current system to SAP S/4HANA as part of the greenfield approach. The goal is thus a complete redesign of the Enterprise Resource Planning (ERP), which is business-critical for innogy Czech, including streamlining and simplifying all processes automated in the system. FPT is responsible for the entire scope of the project, from consulting to planning and implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210817005685/en/
"We entrusted FPT with the upgrade of our SAP system to S/4 HANA because of the company’s expertise, technical capabilities and years of experience in the industry," says Miloš Dušek, Senior Manager of Corporate Applications at innogy Ceska republika. "The project is of great strategic importance for innogy. FPT has proven to be a reliable strategic partner for us and has put together a qualified team to ensure that the first part of the project will be delivered successfully by the end of 2021."
Lighthouse project in the growing market of SAP S/4HANA
The aim of the project is to replace the current SAP ERP system used by innogy Czech in version R/3 ERP Central Component 6.0 EhP 8, which has so far been based on HANA DB2, with S/4HANA Private Cloud Edition. "SAP made an announcement that the company will end the support for its on-premises solutions by 2027. Many companies therefore would want to migrate their system to S/4 HANA in a timely manner," explains Andy Do, Deputy Director/Head of Delivery at FPT Europe. "FPT has strong expertise and many years of experience in cloud migration as well as SAP migration projects, but the project with innogy Czech can be considered as one of the largest end-to-end S/4HANA migration projects for us. It offers FPT a great opportunity to position ourselves as a trusted partner in the field of SAP S/4HANA migration."
The scope of work mentioned above will be applied for 5 companies within innogy Czech Republic group, including innogy Ceska republika a.s., innogy Zakaznicke sluzby, s.r.o., innogy Energie, s.r.o., innogy Energo, s.r.o. and innogy Energetika Plhov-Nachod, s.r.o.
FPT has more than 20 years of experience in providing services related to SAP. With a pool of more than 300 functional and 250 technical consultants, FPT has successfully implemented and rolled out SAP systems for customers in Southeast Asia, Japan and Europe. With SAP S/4HANA, FPT offers a wide range of services such as development, implementation and rollout. FPT also offers its own solutions in the field of Application Managed Services (AMS). FPT’s services in the areas of SAP migration, SAP customization, SAP rollout and SAP Automation Testing help its customers assure smooth and efficient implementation of SAP S/4HANA.
About FPT Europe
FPT Europe, based in Essen, Germany is a part of FPT Corporation - a technology and IT services provider headquartered in Vietnam with nearly US$2 billion in revenue and 36,000 employees. Being a pioneer in digital transformation, the company delivers world-class services in Smart factory, Digital platforms, RPA, AI, IoT, Data Analytics, Mobility, Cloud, Managed Services, Testing. FPT Software has served over 700 customers worldwide, 100 of which are Fortune 500 companies in the industries of Aerospace & Aviation, Automotive, Banking and Finance, Communications, Media and Services, Logistics & Transportation, Utilities, Consumer Packaged Goods, Healthcare, Manufacturing, Public sector, Technology and so on. Established in 2012, FPT Europe has become technology partners of 50 leading companies including Siemens, RWE, Allianz, Schaeffler, Airbus, Carlsberg and many more. For other information, please visit: www.fpt-europe.de
About innogy Czech
innogy Česká republika is a leading energy company in the Czech Republic owned by the largest Hungarian energy group MVM. innogy supplies 1.6 million customers with energy and energy-related innovative services. First class customer service is provided by own call centres and a chain of customer service centres. In addition to gas and electricity supplies, innogy produces heat and electricity in heating plants across the country with an annual heat production of 900,000 GJ. Aside from the core business, innogy focuses on clean mobility, photovoltaics and energy management services. With a nationwide network of 60+ filling stations, own CNG technology production and more than 10 million kg CNG sold annually, innogy is a strong market leader. innogy is also building up a solid position in the fast-growing solar power plants market. The company employs 1,500 highly skilled people and the innogy brand is known to more than 90% of the Czech population.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210817005685/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom